Evidence map›Paper›PMID 38139411›Full record

SynthesisInternational journal of molecular sciences2023

Mesenchymal-Epithelial Transition Kinase Inhibitor Therapy in Patients with Advanced Papillary Renal-Cell Carcinoma: A Systematic Review and Meta-Analysis.

Francisco Cezar Aquino de Moraes, Maysa Vilbert, Vinícius Freire Costa Alves, Gustavo de Oliveira Almeida, Jonathan N Priantti, Thiago Madeira, Carlos Stecca, Marianne Rodrigues Fernandes, Ney Pereira Carneiro Dos Santos

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 2 countries.

Francisco Cezar Aquino de MoraesOncology Research Center, Federal University of Pará, Belem 66075-110, Brazil.ORCID 0000-0003-0623-8135
Maysa VilbertDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5T 2S8, Canada.ORCID 0000-0003-0627-1023
Vinícius Freire Costa AlvesSchool of Medicine, University of São Paulo-USP, São Paulo 14040-904, Brazil.
Gustavo de Oliveira AlmeidaSchool of Medicine, Federal University of Triângulo Mineiro-UFTM, Uberaba 38280-000, Brazil.
Jonathan N PrianttiSchool of Medicine, Federal University of Amazonas-UFAM, Manaus 69020-160, Brazil.ORCID 0000-0002-7804-3022
Thiago MadeiraSchool of Medicine, Federal University of Minas Gerais-UFMG, Belo Horizonte 31270-901, Brazil.ORCID 0009-0007-9497-3039
Carlos SteccaMackenzie Evangelical University Hospital, Curitiba 80710-390, Brazil.
Marianne Rodrigues FernandesOncology Research Center, Federal University of Pará, Belem 66075-110, Brazil.ORCID 0000-0002-1396-3442
Ney Pereira Carneiro Dos SantosOncology Research Center, Federal University of Pará, Belem 66075-110, Brazil.
Universidade Federal do Pará · BRHospital Universitário Evangélico de Curitiba · BRUniversidade de São Paulo · BRUniversidade Federal de Minas Gerais · BRUniversidade Federal do Amazonas · BRUniversidade Federal do Triângulo Mineiro · BRUniversity Health Network · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Papillary subtypes of renal-cell carcinoma (pRCC) represent 10-15% of the cases and commonly have MET alterations. This systematic review and single-arm meta-analysis evaluated MET inhibitor therapy (METi) efficacy and safety in adults with confirmed advanced pRCC. The search strategy included PubMed, Web-of-science, Cochrane, and Scopus. We used the DerSimonian/Laird random effect model for all analyses;

Indexed as

Carcinoma, Renal CellKidney NeoplasmsAdultCohort StudiesEnzyme TherapyHumansProtein Kinase InhibitorsProtein Kinase Inhibitorsadvanced papillary renal-cell carcinomaMET inhibitorsMET status

Identifiers

PMID38139411
PMCPMC10744118
OpenAlexW4389923062

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.